B. Riley analyst Mayank Mamtani reiterates a Buy rating on Viking Therapeutics (VKTX) with a $96 price target after the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback